Current Report Filing (8-k)
October 14 2020 - 04:17PM
Edgar (US Regulatory)
0001330436
false
0001330436
2020-10-13
2020-10-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 13, 2020
LIQUIDIA TECHNOLOGIES, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-38601
|
|
20-1926605
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
419 Davis Drive, Suite 100, Morrisville, North Carolina
|
|
27560
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (919) 328-4400
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock
|
LQDA
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On October 14, 2020, Liquidia Technologies, Inc., a
Delaware corporation, announced that the U.S. Patent Trial and Appeal Board (PTAB) has instituted an inter partes
review against U.S. Patent No. 9,604,901 and concurrently denied institution on U.S. Patent No. 9,593,066, both owned by
United Therapeutics Corporation and listed in the Orange Book for Tyvaso® (treprostinil).
A copy of the press release announcing the decisions of the
PTAB is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
October 14, 2020
|
Liquidia Technologies, Inc.
|
|
|
|
|
|
By:
|
/s/ Steven Bariahtaris
|
|
|
Name:
|
Steven Bariahtaris
|
|
|
Title:
|
Interim Chief Financial Officer
|
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Mar 2023 to Mar 2024